格列美脲联合吡格列酮治疗老年2型糖尿病合并高血压患者的疗效分析

摘要:目的 探讨格列美脲联合吡格列酮治疗老年2型糖尿病合并高血压患者的疗效。方法 选取2017年6月~2018年5月我院收治的2型糖尿病合并高血压患者120例，按随机数字表法分为观察组和对照组，各60例。对照组给予吡格列酮，观察组在对照组的基础上给予格列美脲，比较两组治疗前、治疗后第6个月的血糖、血脂、血压水平以及不良反应发生率。结果 治疗后，观察组FPG、HbA1c低于对照组[（6.25±0.79）mmol/L vs（6.73±0.81）mmol/L、（5.90±1.12）% vs（6.39±1.33）%]，差异有统计学意义（P＜0.05）。观察组TC、TG低于对照组[（4.76±0.96）mmol/L vs（5.22±1.01）mmol/L、（1.60±0.64）mmol/L vs（1.60±0.64）mmol/L]，差异有统计学意义（P＜0.05）；两组LDL-C、HDL-C比较，差异无统计学意义(P＞0.05)。观察组SBP低于对照组[（125.36±12.87）mmHg vs （132.35±13.58）mmHg]，差异有统计学意义（P＜0.05）；两组DBP比较，差异无统计学意义(P＞0.05)。观察组不良反应发生率为6.67%，低于对照组的10.00%，但差异无统计学意义（P＞0.05）。结论 吡格列酮联合格列美脲能有效改善老年2型糖尿病合并高血压患者的血糖、血脂和血压水平，且联合用药改善效果优于单独用药，且具有较高的安全性。

Efficacy Analysis of Glimepiride Combined with Pioglitazone in the Treatment of Elderly Patients with Type 2 Diabetes Mellitus Complicated with Hypertension

Abstract:Objective To investigate the efficacy of glimepiride combined with pioglitazone in the treatment of elderly patients with type 2 diabetes mellitus complicated with hypertension. Methods A total of 120 patients with type 2 diabetes mellitus complicated with hypertension admitted to our hospital from June 2017 to May 2018 were enrolled. The patients were divided into observation group and control group by random number table, 60 cases each. Pioglitazone was given to the control group, and glimepiride was given to the observation group on the basis of the control group. The blood glucose, blood lipid and blood pressure levels and the incidence of adverse reactions were compared before treatment and at 6 months after treatment. Results After treatment, the FPG and HbA1c in the observation group were lower than the control group[(6.25±0.79)mmol/L vs (6.73±0.81)mmol/L, (5.90±1.12) % vs (6.39±1.33)%], the difference was statistically significant (P<0.05). The TC and TG in the observation group were lower than those in the control group[(4.76±0.96) mmol/L vs (5.22±1.01)mmol/L, (1.60±0.64)mmol/L vs (1.60±0.64)mmol/L], and the difference was statistically significant (P<0.05).There was no significant difference between the two groups in LDL-C and HDL-C (P>0.05). The SBP of the observation group was lower than that of the control group[(125.36±12.87)mmHg vs (132.35±13.58)mmHg], the difference was statistically significant (P<0.05).There was no significant difference in DBP between the two groups (P>0.05). The incidence of adverse reactions in the observation group was 6.67%, which was lower than that in the control group, but the difference was not statistically significant (P>0.05). Conclusion Pioglitazone combined with glimepiride can effectively improve blood glucose, blood lipids and blood pressure in elderly patients with type 2 diabetes mellitus complicated with hypertension, and the combined use of the drug is better than the single drug, and has a high safety.